Bone scintigraphy, commonly referred to as bone scan (also skeletal scintigraphy) is a special nuclear medical method for examination that measures the traces of radioactive agent, e.g. previously administered radioactive medication accumulated inside the bone. The distribution patterns and the amount of tracers allow for indications of an increased metabolism, such is generally found with metastasic prostate cancer.
In contrast to radiological examination procedures (CT/MRT), which primarily show the changes of the bone structure, scintigraphy primarily provides information about abnormal changes in the bone metabolism. Abnormal scintigrafic findings are, however, no evidence for metastasis, since they can also occur as a result of benign bone disease or deterioration of the joints (arthritis).
Bone scintigraphy should always be performed to rule out bone metastasis in all patients with prostate specific antigen level (PSA) above 20 ng/ml, or with aggressive tumor types (Gleason score above 7).
In a recently published ranking of physicians, Dr. Stephan Neubauer, Chief of Urology at the West-German Prostate Center, was again voted to be one of the best urologists in Germany
The Prostate Cancer Treatment Research Foundation has recently launched a new web site, including the new interactive charts showing the treatment comparison data compiled by the Prostate Cancert Research Study Group. This new resource will help you make better decisions about your treatment choice. The web site features step-by-step instructions on how to identify cancer risk groups, and compare the effectiveness of the various prostate cancer treatments, as well as detailed commentary about the treatment results. You can see the main page of the web site here: www.pctrf.org
PSMA, ein neuer radioaktiver Marker, erkennt Tumorherde und Metastasen präziser als das Cholin-PET/CT.
Die irreversible Electroporation (IRE) ist eine experimentelle Methode zur Zerstörung von Tumorzellen durch elektrischen Strom